2023
A Phase I, First-in-Human Study of PRL3-zumab in Advanced, Refractory Solid Tumors and Hematological Malignancies
Chee C, Ooi M, Lee S, Sundar R, Heong V, Yong W, Ng C, Wong A, Lim J, Tan D, Soo R, Tan J, Yang S, Thura M, Al-Aidaroos A, Chng W, Zeng Q, Goh B. A Phase I, First-in-Human Study of PRL3-zumab in Advanced, Refractory Solid Tumors and Hematological Malignancies. Targeted Oncology 2023, 18: 391-402. PMID: 37060431, PMCID: PMC10192144, DOI: 10.1007/s11523-023-00962-w.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaAdvanced solid tumorsFirst-in-human studyEuropean Leukemia NetworkSolid tumorsHematologic malignanciesTreatment-emergent adverse eventsHuman antibodiesDose-escalation cohortsDose-limiting toxicityGrade 2 vomitingPRL-3Refractory solid tumorsResponse Evaluation CriteriaSolid tumor patientsDose-expansion cohortReduced tumor growthFirst-in-humanPhase IStable diseaseStoma outputEvaluation CriteriaMyeloid leukemiaPharmacodynamic relationshipsAdverse events
1995
Biological activity and immunological reactivity of human prolactin mutants
Rhee H, Sun Z, Kim S, Goffin V, Martial J, Dannies P. Biological activity and immunological reactivity of human prolactin mutants. Endocrinology 1995, 136: 4990-4995. PMID: 7588233, DOI: 10.1210/endo.136.11.7588233.Peer-Reviewed Original ResearchConceptsSerine 90Cystine loopBiological activityRat pituitary cell lineHuman PRLPituitary cell lineWild typeCertain fishPRL-3MutantsTryptophan fluorescenceCell linesMutationsFishT mutationCell assayPRL storageImmunological reactivityImmunological propertiesSerineConcentration of ureaActivityConservationSpacial requirementsLoopBiological activity and immunological reactivity of human prolactin mutants
Rhee H, Sun Z, Kim S, Goffin V, Martial J, Dannies P. Biological activity and immunological reactivity of human prolactin mutants. Endocrinology 1995, 136: 4990-4995. DOI: 10.1210/en.136.11.4990.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply